Dermira, Inc. – DERM – FDA Approval

Dermira, Inc. – DERM has upcoming FDA Approval date of June 30th 2018 for glycopyrronium tosylate (formerly DRM04). FDA has completed its filing review and the NDA for glycopyrronium tosylate is sufficiently complete to permit a substantive review. Drug User Fee Act target date for the completion of the FDA’s review of the NDA is June 30, 2018.

finviz dynamic chart for  DERM

 


Sharing is Caring:
ZitroStocks

Author: ZitroStocks

Welcome to ZitroStocks, hope you enjoy your visit. You are welcome to ask questions and participate in discussions.

Leave a Reply

Your email address will not be published. Required fields are marked *


One thought on “Dermira, Inc. – DERM – FDA Approval”

  1. Now that DERM has funds and the offering is out of the way, this might see a decent run up into the FDA approval.
    Looking for Entry $8-$8.50, Might go over $10, Stop below $8.